Insights with Goldman Sachs Part 3: Regulatory dynamics and research trends
FDA had a record year for approvals in 2023 and continues to create regulatory pathways. The advice for biopharma: keep pushing regulatory boundaries. And drug development strategies should emphasize cross-pollination across therapeutic areas.
Disclaimer: The views and opinions that the panelists express are their own and are for informational purposes only. They do not constitute a recommendation by Goldman Sachs Asset Management for you to take any action. This video includes the perspectives of Amy McKee, our previous Chief Medical Officer & Global Head, Oncology Center of Excellence. Amy left Parexel in August 2024.
Related Insights
Video
Insights with Goldman Sachs Part 4: The impact of the Inflation Reduction Act
Jan 26, 2024
Video
Insights with Goldman Sachs Part 5: Pioneering new approaches, technologies, and AI to drive innovation
Jan 26, 2024
Video
Insights with Goldman Sachs Part 6: Generating investor interest
Jan 26, 2024
Video
Insights with Goldman Sachs Part 1: Future predictions
Jan 26, 2024
Video
Insights with Goldman Sachs Part 2: How pharma is using M&A for growth and innovation
Jan 26, 2024